Acceleron Pharma

Acceleron Pharma, Inc.
Traded as NASDAQ: XLRN
Industry Biotechnology
Founded December 2003 (2003-12)
Headquarters Cambridge, Massachusetts, United States
Key people
 John Knopf (CEO; 2003–Present)
Steve Ertel (COO; 2006–Present)
Matt Sherman (CMO; 2006–Present)
Kevin McLaughlin (CFO; 2010–Present)
[1]
Website acceleronpharma.com

Acceleron Pharma, Inc. is a public American "clinical stage biopharmaceutical company" based in Boston, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

History

John Knopf, Jasbir Seehra, Tom Maniatis, Mark Ptashne and Wylie Vale formed the company in Cambridge, Massachusetts.[2][3] The company began with a venture capital investment and opened its first laboratory in December 2003.[2] [4]

The company tendered an initial public offering in September 2013.[5]

References

  1. ↑ http://www.acceleronpharma.com/our-company/management/
  2. 1 2 Cooke, Philip, ed. (2007). "Local clusters and global networks". Regional Knowledge Economies (Google eBook). New horizons in regional science. United Kingdom: Edward Elgar Publishing. p. 79. ISBN 9781847206930.
  3. ↑ McLellan, Dennis (January 18, 2012). "Wylie W. Vale Jr. dies at 70; researcher helped discover stress hormone". Los Angeles Times.
  4. ↑ http://files.shareholder.com/downloads/AMDA-23MZWJ/552975461x7981394x690792/4DD0FFF0-C9CC-4E40-8310-E252D74ABBFC/BioCentury-Emerging-Co-Acceleron.pdf
  5. ↑ Huggett, Brady (December 2013). "Burning Bright". Nature Biotechnology 31 (12). pp. 1068–71.
This article is issued from Wikipedia - version of the Thursday, October 01, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.